Salute e Benessere

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2025_14_Trading_By_Management
Nasdaq GlobeNewswire
26/03/2025

Assisted Reproductive Technology Market worth US$6.02 Billion by 2030 with 7.0%…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91934243 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91934243 Browse in-depth TOC on "Assisted Reproductive Technology Market" 200 - Tables 100 - Figures 300 - Pages By Based on type,Equipment maintains the largest market share in the assisted reproductive technology (ART) market because they are at the forefront of fertility treatment and because...
PR Newswire
26/03/2025

CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising…

The therapy plays a critical role in treating relapsed and refractory hematologic cancers. In the U.S., hematologic cancers such as leukemia, lymphoma, and myeloma are diagnosed approximately every three minutes, highlighting an urgent need for innovative treatments. With government support and favorable reimbursement policies, the eligibility of hematologic cancer patients for CAR T-cell therapy increased from 2.7% in 2017 to 3.9% in 2023. Additionally, ongoing research focuses on expanding…
PR Newswire
26/03/2025

Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to…

Adding ARMMs to the company's eTurna® LNP delivery platform greatly expands the reach of Turn Bio's ERA® technology, which uses mRNA to produce proteins that translate the cellular epigenome to restore function and fight conditions caused by aging. Adding ARMMs to the company's eTurna® LNP delivery platform greatly expands the reach of Turn Bio's ERA® technology, which uses mRNA to produce proteins that translate the cellular epigenome to restore function and fight conditions caused by aging...
PR Newswire
26/03/2025

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary…

Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of directors to carry out a share capital increase of NOK 0.70 through the issuance of seven (7) new shares in the Company in order to achieve a desirable ratio for the reverse share split.The Company has received the following notification of a transaction made by a close associate of a primary insider: Radforsk...
Nasdaq GlobeNewswire
26/03/2025

Homestyler Aims to Accelerate Global Expansion and Innovation Following the…

Homestyler shared AI-driven solutions to address the various pain points faced by three distinct groups: Homestyler shared AI-driven solutions to address the various pain points faced by three distinct groups: AI-Powered Innovation for the Future of Home Design Committed to solving space design challenges for professionals and enthusiasts alike, Homestyler continues to push the boundaries of AI-driven efficiency. As part of its 2025 strategy, the company will focus on three key areas:...
PR Newswire
26/03/2025

Zelluna ASA [ZLNA]: Share capital increase resolution

Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the " Company "), where it was resolved to carry out a reverse share split in the ratio 10:1 and to grant the Company's board of directors a general authorisation to issue shares. As the Company's shares cannot be fully divided by 10, the Company's board of directors has today resolved a share capital increase of NOK 0.70 through the issuance of…
Nasdaq GlobeNewswire
26/03/2025

Lundbeck held its Annual General Meeting on 26 March 2025 at the company's…

The Remuneration Report for 2024 was approved in the advisory vote. The Remuneration Report for 2024 was approved in the advisory vote. Dorothea Wenzel, Lene Skole-Sørensen,Lars Erik Holmqvist,Jeffrey Berkowitz,Santiago Arroyo, andJakob Riiswere re-elected to the Board of Directors.Lars Greenwas elected as a new member of the Board of Directors. The Board of Directors of Lundbeck will hereafter comprise: Immediately after the general meeting, the Board of Directors...
PR Newswire
26/03/2025

Supira Medical Secures $120M Oversubscribed Series E Financing and Completes…

Additionally, Supira welcomes Dr. Christopher Shen, Partner, Novo Holdings US to its Board of Directors. "We believe there is a massive unmet need for next-generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients," stated Dr. Shen. "The Supira team has built a strong clinical foundation to further validate their advanced low-profile, high flow technology platform in two important segments of…
PR Newswire
26/03/2025

Lutris Pharma to Present at the American Association for Cancer Research Annual…

Presentation Details: Presentation Details: About EGFR Inhibitor-Induced RashEGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various...
PR Newswire
26/03/2025

Novo Holdings participates in €23 million Series A for Tribune Therapeutics to…

Through a Pioneer Innovator Grant, the Novo Nordisk Foundation – whose assets Novo Holdings manages – partially funded scientific discoveries at the Oslo University Hospital by Professor Håvard Attramadal and Ole J. Kaasbøll that led to Tribune's formation. The Pioneer Innovator grant programme is designed to advance science-based discoveries in sustainability and health by funding experiments and activities that push ideas toward proof-of-concept and beyond, in line with Novo Nordisk…
PR Newswire
26/03/2025

Financière de Tubize - Convening of the ordinary and extraordinary general…

Convening of the Ordinary and Extraordinary General Meetings of shareholders of 25 April 2025 The shareholders are invited to attend the ordinary and extraordinary general meetings, which will take place on Friday 25th of April 2025 at 11:00AM and 12:00PM respectively, at the registered seat in 1070 Brussels (Anderlecht), Allée de la Recherche 60.The board of directors has decided not to organize a remote general meeting in accordance with article 7:137, §1 of the Companies and Associations...
Nasdaq GlobeNewswire
26/03/2025

Beauty Supplements Market worth $5.76 billion by 2030- Exclusive Report by…

Browse in-depth TOC on "Beauty Supplements Market" Browse in-depth TOC on "Beauty Supplements Market" 250 – Tables70 – Figures350 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=165507335 The powder segment holds the significant market share in the beauty supplements segment. Powdered beauty supplements are universally favored due to their high bioavailability, adaptive dosing, and convenience of consumption. They have a...
PR Newswire
26/03/2025

Zymeworks Announces Participation in Upcoming Investor Conferences

Needham 24 thAnnual Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 8 at 9:30 am Eastern Time (ET).Stifel 2025 Virtual Targeted Oncology Forum: Zymeworks' management will participate in virtual one-on-one meetings and a fireside chat on April 9 at 12:30 pm ET.About Zymeworks Inc.Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of...
Nasdaq GlobeNewswire
26/03/2025

Alma introduces Alma Harmony, a state-of-the-art aesthetic platform for…

Alma Harmony takes a huge leap forward in patient personalization. The new evolution is powered by the five of the most in-demand technologies, brilliantly integrated to provide a comprehensive range of treatments for almost any indication or skin type: the Q-Switch Laser stimulates collagen and treats pigmentation by targeting dermal layers, the Fractional Ablative laser creates pixel-sized perforations in the skin, inducing rejuvenation while preserving surrounding tissues for quicker…
PR Newswire
26/03/2025

SIBIONICS GS3: The World's Thinnest CGM Debuts at ATTD 2025

With its ultra-compact design and 3-second activation, GS3 quickly became a highlight at ATTD 2025 with its revolutionary thinness of just 2.9mm, comparable to a small coin. It offers: With its ultra-compact design and 3-second activation, GS3 quickly became a highlight at ATTD 2025 with itsrevolutionary thinness of just 2.9mm, comparable to a small coin. It offers: In-Depth Exploration of CGM & CKM in Clinical Applications At ATTD 2025, SIBIONICS hosted the SIBIONICS Symposium,...
PR Newswire
26/03/2025

NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC…

The adopted wording for the newly extended indication is: The adopted wording for the newly extended indication is: "Slenyto® is indicated for the treatment of insomnia: "We recognise there is significant unmet need and high demand for addressing sleep maintenance and duration as well as sleep initiation difficulties of children withADHD,who suffer from impaired sleep.The European Commission (EC) granted marketing authorization (MA) of Slenyto ®for insomnia in children with ADHD...
PR Newswire
26/03/2025

Procare Health released results from their latest clinical trial, Paloma 2…

MADRID, March 25, 2025 /PRNewswire/ -- Key Findings and Scientific Evidence MADRID , March 25, 2025 /PRNewswire/ --Key Findings and Scientific Evidence ThePaloma 2clinical trial, conducted in19 Spanish hospitals, involved164 womenwith an average age of41.13 years. All participants tested positive forhigh-risk HPVand presented with low-grade cervical lesions. The trial compared two groups: one received intensive treatment withPapilocare®, while the other...
PR Newswire
26/03/2025

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has...
Nasdaq GlobeNewswire
26/03/2025

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development…

During his thirteen years at Pieris, Shane played a pivotal role developing its diverse pipeline of clinical programs in immuno-oncology and respiratory diseases – progressing nine programs into the clinic. Prior to that he was Director of Research at AIM-listed Fusion Antibodies, building out its research team and establishing its technology platform. With over 60 intellectual property rights to his name, he is a recognized leader in drug development and a regular reviewer for prominent…
PR Newswire
26/03/2025

Photocure appoints Jane Healy as Vice President and General Manager EMEA

In her most recent role, Jane Healy was VP EMEA for the Peripheral Interventions Division for Boston Scientific, responsible for driving the growth strategy for the region. She brings a blend of strong commercial acumen, results orientation and a passion for enabling and driving results through her teams. Jane Healy holds a BA (Hons) in Modern Languages from Cambridge University and she speaks English, French, German and Italian. In her most recent role,Jane Healywas VP EMEA for the...
PR Newswire
26/03/2025

Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for…

The pre-IND meeting provided an opportunity for the Company to discuss its Investigational New Drug (IND) development plan and receive FDA guidance on nonclinical and clinical study requirements for its new drug candidate PTX-252. In the written response from the Division of Hematologic Malignancies, the FDA provided constructive feedback and expressed support for Pleco's proposed development strategy.PTX-252 is a small molecule designed to remove toxic heavy metals from the tumour...
Nasdaq GlobeNewswire
26/03/2025

FDA Issues Nyxoah an Approvable Letter for its Genio® System

INSIDE INFORMATION REGULATED INFORMATIONFDA Issues Nyxoah an Approvable Letter for its Genio® SystemMont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company's Pre-Market...
Nasdaq GlobeNewswire
26/03/2025

ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to…

The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility studyThe Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at various locations along the spinal cord to enable restoration of movement and other functions EINDHOVEN, the Netherlands, March26, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation...
Nasdaq GlobeNewswire
26/03/2025
Altri  Comunicati